1. |
汪晓东, 林容若, 刘健博, 等. 数据库建设第七部分: 结直肠癌手术特征的标签与结构化(二). 中国普外基础与临床杂志, 2020, 27(10): 1295-1300.
|
2. |
汪晓东, 林容若, 刘健博, 等. 数据库建设第七部分: 结直肠癌手术特征的标签与结构化(一). 中国普外基础与临床杂志, 2020, 27(9): 1150-1152.
|
3. |
CSCO 临床数据委员会. CSCO database. https://www.sinyoo.net/csco/. 2015.
|
4. |
博识医疗云公司数据库. https://www.boshicloud.com/. 2014.
|
5. |
明智医疗公司数据库. http://www.wiseltd.cn/. 2015.
|
6. |
中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020 年版). 中华外科杂志, 2020, 58(8): 561-585.
|
7. |
Iwamoto S, Maeda H, Hazama S, et al. Efficacy of CapeOX plus cetuximab treatment as a first-line therapy for patients with extended RAS/BRAF/PIK3CA wild-type advanced or metastatic colorectal cancer. J Cancer, 2018, 9(22): 4092-4098.
|
8. |
Yamada Y, Denda T, Gamoh M, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase Ⅲ, noninferiority trial. Ann Oncol, 2018, 29(3): 624-631.
|
9. |
刘勇, 汪晓东, 朱佳怡, 等. 数据库研究第十部分: 结直肠癌的辅助治疗特征分析. 中国普外基础与临床杂志, 2021, 28(7): 937-944.
|
10. |
Howells LM, Iwuji COO, Irving GRB, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase Ⅱa trial. J Nutr, 2019, 149(7): 1133-1139.
|
11. |
Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 2004, 22(2): 229-237.
|
12. |
Hwang J, Marshall JL. Targeted therapy for colorectal cancer. Curr Opin Investig Drugs, 2006, 7(12): 1062-1066.
|
13. |
Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw, 2009, 7(8): 838-881.
|